MEDizzy
MEDizzy
Amy Kosran
Amy Kosran7 months ago
Semaglutide 'A New Pathway' to CVD Risk Reduction: SELECT

Semaglutide 'A New Pathway' to CVD Risk Reduction: SELECT

The weight loss drug showed a consistent reduction in major cardiovascular events over a 3-year follow up in patients with a history of heart disease who were overweight or obese.

Source: https://www.medscape.com/viewarticle/998373?src=mbl_msp_android&ref=share
0
Other commentsSign in to post comments. You don't have an account? Sign up now!

Recent MCQs















Show more MCQs

Recent flashcard sets















Show more flashcards